期刊文献+

造血干细胞移植后CIK细胞生物治疗的临床观察 被引量:3

Clinical observation of CIK cells biological therapy after haemopoietic stem cells transplantation
下载PDF
导出
摘要 目的:观察细胞因子诱导的杀伤细胞(CIK细胞)对造血干细胞移植后血液肿瘤患者维持治疗的疗效。方法2005年9月至2010年6月收治血液恶性肿瘤患者12例,其中行自体造血干细胞移植8例,异基因造血干细胞移植4例;移植造血重建后1~3个月内,利用血细胞分离机分离患者(自体移植)及供者(异体移植)的外周血单个核细胞,在体外用多种细胞因子[抗CD3单克隆抗体(OKT3)、白介素-2(IL-2)、干扰素-γ(IFN-γ)等)]共同培养后获得CIK细胞,分次回输给患者。随访观察患者接受治疗后血常规及骨髓等指标的变化及不良反应,同时记录患者的生存期。结果8例自体干细胞移植患者有2例复发,其中1例17个月后死亡,其余6例长期生存;4例异体干细胞移植患者有1例复发,5个月后死亡,其余3例长期生存;4例患者静脉滴注CIK细胞时出现畏寒、寒战、发热,经对症处理均缓解,其余未见不良反应。结论造血干细胞移植后CIK细胞生物治疗延长了患者的生存期,改善了患者的生活状况,未见明显不良反应。 Objective To investigate the effects of the maintenance treatment of adoptive immunotherapy of cytokine in-duced killer(CIK) cells for the patients with malignant hematopathy previously given haemopoietic stem cell transplantation (HSCT). Methods Among the 12 patients with malignant hematopathy ,who were received from September 2005 to June 2010 ,8 patients were treated with auto-hematopoietic stem cell transplantation (auto-HSCT) and 4 with allo-hematopoietic stem cell transplanta-tion (allo-HSCT). It was used the blood cell separator to separate the peripheral blood mononuclear cells of the patients (auto transplantation) and the suppliers(allotransplantation) within 1-3 months after rebuilding of transplantation and blooding. The CIK cells were obtained after cultivating with various cells such as OKT3,IL-2,IFN-γtogether in vitro and retransformed to the patients in times. Follow-up observed the indicators of blood routine examination and bone marrow as well as adverse reaction ,and recorded the patients′lifetime. Results 2 cases relapsed among 8 patients with auto-HSCT including 1 died 17 months after the treatment,and the other 6 cases had long-term survival;1 case recurred among 4 patients with allo-HSCT,and died after 5 months,the other 3 cases had long-term survival. In the process of CIK for intravenous injection,4 cases had chills,shiver,fever, and got alleviated after symptomatic treatment ,there were no adverse reaction on the others. Conclusion CIK biological therapy after haemopoietic stem cells transplantation extended the survival time of the patients ,improved their life condition without obvi-ous adverse reaction.
出处 《现代医药卫生》 2014年第11期1639-1640,1643,共3页 Journal of Modern Medicine & Health
关键词 造血干细胞移植 移植 自体 杀伤细胞 细胞因子类 干细胞移植 基因 免疫疗法 过继 血液肿瘤 Hematopoietic stem cell transplantation Transplantation,autologous Killer cells Cytokines Stem cell transplantation Genes Immunotherapy,adoptive Hematologic neoplasms
  • 相关文献

参考文献2

二级参考文献20

  • 1朱建平,徐鸣,汝美华.CIK细胞临床应用技术规范探讨[J].中国医药生物技术,2007,2(2):148-150. 被引量:12
  • 2薛陆军,崔晓蔷,张彦,董明娥.中西医结合介入治疗中晚期非小细胞肺癌120例[J].陕西中医,2004,25(12):1059-1061. 被引量:6
  • 3马建青,陈凡.艾迪注射液配合放化疗治疗非小细胞肺癌58例[J].陕西中医,2006,27(4):392-394. 被引量:9
  • 4巩新建,刘军权,李玺,王涛,冯霞,陈复兴.进展期胃癌术后自身CIK细胞和树突状细胞联合治疗的临床观察[J].中国肿瘤临床,2007,34(14):803-806. 被引量:28
  • 5Schmidt-Wolf IG, Lefterova P, Johnston V, et al. Sensitivity of multidrug, resistant tumor cell lines to immunologic effector cells [J]. Cell Immunol, 1996,169 : 85-90.
  • 6Marten A, Sch6ttker B, Ziske C, et al. Increase of the immunostimulatory effect of dendritic cells by pulsing with CA19-9 protein[J]. Immunother, 2000,23: 464-472.
  • 7Sehmidt Wolf IGH, Lefterova P, Johnston V, et al. Sensitivity of multidrug resistant tumor cell lines to immunologic effector cells [J]. Cell Immunol, 1996,169 : 85-90.
  • 8Verneris MR, Komacker M, Mailander V, et al. Resistance of ex vivo expanded CD3 CD56 T cells to Fas mediated apoptosis [J]. Cancer Immunol Immunother, 2000,49 : 335-345.
  • 9Lu PH , Negrin RS. A novel population of expanded human CD3-CD56-cells derived from T cells with potent in vivo antitumor activity in mice with severe combined immunodeficieney [J]. J Immunol, 1994, 153 (4) : 1687- 1696.
  • 10Li H,Wang C,Yu J,et al.Dendritic cell-activated cytokine-induced killer cells enhance the anti-tumor effect of chemotherapy on non-small cell lung cancer in patients after surger[J].Cytotherapy,2009,11(8):1076-1083.

共引文献9

同被引文献65

  • 1韩悦,吴德沛,金正明,孙爱宁,何广胜,陈苏宁,王秀丽,卢晓旭.抗CD33单抗联合造血干细胞移植治疗难治继发性急性髓系白血病一例[J].中华血液学杂志,2006,27(1):31-31. 被引量:2
  • 2沈志祥,朱雄增.恶性淋巴瘤[M].北京:人民出版社,2011:701.
  • 3BACCAR ANI M,DEININGER M W,ROSTI G,et al.European Leukemia Net recommendations for the management of chronic myeloid leukemia:2013[J].Blood,2013,122(6):872-884.
  • 4LINN Y C,HUI K M.Cytokine-induced NK-like T cells:from bench to bedside[J].Journal of Biomedicine and Biotechnology,2010,2010:435745.
  • 5SCHMIDT-WOLF I G,LEFTEFTEROVA P,JOHNSTON V,et al.Propagation of large numbers of T cells with natural killer cell markers[J].British Journal of Haematology,1994,87(3):453-458.
  • 6XING D,ZHAO Y.DC-CIK biotherapy for a recurrent benign lymphoepithelial lesion of the salivary gland:A case report and literature review[J].Experimental and Therapeutic Medicine,2014,8(5):1565-1568.
  • 7HONSCHA C,BORCK Y,ZHOU H,et al.Clinical trials on CIK cells:first report of the international registry on CIK cells(IRCC)[J].Journal of Cancer Research and Clinical Oncology,2011,137(2):305-310.
  • 8FINKE S,TROROJANECK B,LEFTEROVA P,et al.Increase of proliferation rate and enhancement of antitumor cytotoxicity of expanded human CD3+CD56+immunologic effector cells by receptor-mediated transfection with the interleukin-7 gene[J].Gene Therapy,1998,5(1):31-39.
  • 9HOYLE C,BANGS C D,CHANG P,et al.Expansion of Philadelphia chromosome-negative CD3+CD56+cytotoxic cells from chronic myeloid leukemia patients:in vitro and in vivo efficacy in severe combined immunodeficiency disease mice[J].Blood,1998,92(9):3318-3327.
  • 10JENNIFER C F.Breakthrough of the year 2013.Cancer immunotherapy[J].Science,2013,342(6165):1432-1433.

引证文献3

二级引证文献4

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部